Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabina Chiaretti

Showing results (161-170 of 172) with videos related to

Pageof 18
Sort By:
Blood Advances|June 5, 2023
Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trialRenato Bassan, Sabina Chiaretti, Irene Della Starza, et al.
British Journal of Haematology|November 6, 2022
Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL studyMichelina Dargenio, Massimiliano Bonifacio, Sabina Chiaretti, et al.
The Lancet. Haematology|June 18, 2025
Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trialElias Jabbour, Federico Lussana, Pilar Martínez-Sánchez, et al.
Blood|February 26, 2025
Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: the GIMEMA LAL2317 phase 2 studyRenato Bassan, Sabina Chiaretti, Irene Della Starza, et al.
Haematologica|May 30, 2020
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913Sabina Chiaretti, Monica Messina, Irene Della Starza, et al.
Annals of Hematology|August 26, 2025
Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL groupDavide Lazzarotto, Anna Maria Testi, Matteo Fanin, et al.
Bone Marrow Transplantation|June 2, 2025
Outcomes of allogeneic stem cell transplant in adult Philadelphia negative acute lymphoblastic leukemia patients treated with the pediatric-inspired GIMEMA 1913 protocol. A Campus ALL studyGianluca Cavallaro, Davide Lazzarotto, Chiara Pavoni, et al.
Leukemia|October 10, 2019
In Ph+BCR-ABL1<sup>P210+</sup> acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalentMichele Baccarani, Ilaria Iacobucci, Sabina Chiaretti, et al.
American Journal of Hematology|January 14, 2014
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patientsRobin Foà, Ilaria Del Giudice, Antonio Cuneo, et al.
Haematologica|January 15, 2026
Real-life management of 476 older adults with Philadelphianegative acute lymphoblastic leukemia: a Campus ALL studyMarco Cerrano, Davide Lazzarotto, Eleonora Boscaro, et al.
Pageof 18

Showing results (161-170 of 172) with videos related to

Sort By:
Pageof 18
Blood Advances|June 5, 2023
Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trialRenato Bassan, Sabina Chiaretti, Irene Della Starza, et al.
British Journal of Haematology|November 6, 2022
Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL studyMichelina Dargenio, Massimiliano Bonifacio, Sabina Chiaretti, et al.
The Lancet. Haematology|June 18, 2025
Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trialElias Jabbour, Federico Lussana, Pilar Martínez-Sánchez, et al.
Blood|February 26, 2025
Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: the GIMEMA LAL2317 phase 2 studyRenato Bassan, Sabina Chiaretti, Irene Della Starza, et al.
Haematologica|May 30, 2020
Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913Sabina Chiaretti, Monica Messina, Irene Della Starza, et al.
Annals of Hematology|August 26, 2025
Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL groupDavide Lazzarotto, Anna Maria Testi, Matteo Fanin, et al.
Bone Marrow Transplantation|June 2, 2025
Outcomes of allogeneic stem cell transplant in adult Philadelphia negative acute lymphoblastic leukemia patients treated with the pediatric-inspired GIMEMA 1913 protocol. A Campus ALL studyGianluca Cavallaro, Davide Lazzarotto, Chiara Pavoni, et al.
Leukemia|October 10, 2019
In Ph+BCR-ABL1<sup>P210+</sup> acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalentMichele Baccarani, Ilaria Iacobucci, Sabina Chiaretti, et al.
American Journal of Hematology|January 14, 2014
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patientsRobin Foà, Ilaria Del Giudice, Antonio Cuneo, et al.
Haematologica|January 15, 2026
Real-life management of 476 older adults with Philadelphianegative acute lymphoblastic leukemia: a Campus ALL studyMarco Cerrano, Davide Lazzarotto, Eleonora Boscaro, et al.
Pageof 18